2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions

View by Date

Wednesday, September 25, 2019

1:15pm-2:45pm: The cognitive profile associated with mild parkinsonian signs in a British Birth Cohort at age 69-71

S. Buchanan, C. Lane, K. Lu, T. Parker, S. James, A. Keshavan, S. Keuss, H. Murray-Smith, A. Wong, D. Cash, W. Coath, S. Crutch, N. Fox, M. Richards, A. Schrag, J. Schott (London, United Kingdom)

Cognition and Cognitive Disorders · Agora 3 East, Level 3

1:15pm-2:45pm: The comparison of cognitive function between normal and abnormal FDG-PET in non-demented Parkinson’s disease

SJ. Kim, EJ. Chung (Busan, Republic of Korea)

Cognition and Cognitive Disorders · Agora 3 East, Level 3

1:15pm-2:45pm: The concept of a ‘long lesion’ in thalamic/Zona inserta DBS for MS tremor suppression

S. Alusi, B. Hammersley, J. Somerset, P. Eldridge, J. Farah (Liverpool, United Kingdom)

Surgical Therapy · Les Muses Terrace, Level 3

1:15pm-2:45pm: The contribution of striatal dopamine to feedforward motor control during gait initiation in Parkinson’s disease

G. Brandt, C. Palmisano, J. Brumberg, N. Pozzi, A. Canessa, G. Pezzoli, I. Isaias, J. Volkmann (Würzburg, Germany)

Physiology and Pathophysiology · Les Muses, Level 3

1:15pm-2:45pm: The Dutch Parkinson and Cognition study (DUPARC): Cognitive impairment and cholinergic innervation in de novo Parkinson’s Disease patients

S. Vander Zee, JM. Boertien, MJJ. Gerritsen, JM. Spikman, T. van Laar (Groningen, Netherlands)

Neuroimaging · Les Muses Terrace, Level 3

1:15pm-2:45pm: The Economic Burden of Parkinson’s Disease (PD) in the United States

C. Tanner, R. Albin, N. Dahodwala, R. Dorsey, W. Yang, L. Schmiel, I. Cintina, C. Kopil, J. Beck, J. Hamilton (San Francisco, CA, USA)

Epidemiology · Les Muses, Level 3

1:15pm-2:45pm: The effect of dopaminergic therapy on functional connectivity in patients with Parkinson’s disease and visual hallucinations

A. Powell, J. Shine, S. Lewis (Sydney, Australia)

Non-Motor Symptoms · Agora 3 West, Level 3

1:15pm-2:45pm: The effect of istradefylline on mood disorders in Parkinson’s disease

H. Nagayama, O. Kano, H. Murakami, M. Hamada, R. Sengoku, Y. Shim, T. Toda (Tokyo, Japan)

Non-Motor Symptoms · Agora 3 West, Level 3

1:15pm-2:45pm: The effect of Levodopa-Carbidopa Intestinal Gel on Non-Motor Symptoms, Specificly Autonomic Dysfunctions

H. Ekmekci, M. Gültekin (Ankara, Turkey)

Non-Motor Symptoms · Agora 3 West, Level 3

1:15pm-2:45pm: The Effects of Time-Varying Caloric Vestibular Stimulation Therapy on Cognition Impairment in Parkinson’s Disease

K. Ade, A. Podlewska, S. Banducci, T. Pellat-Higgins, M. Bodani, M. Sakel, L. Smith, D. Attix, P. Lewitt, D. Wilkinson (Raleigh, NC, USA)

Cognition and Cognitive Disorders · Agora 3 East, Level 3